Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 2/20 | 1.00 |
| ▸ | RARB | P10826 | 15/20 | 0.77 |
| ▸ | RARG | P13631 | 15/20 | 0.77 |
| ▸ | RARA | P10276 | 14/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.51 |
| ▸ | RXRA | P19793 | 5/20 | 0.51 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tazarotenic Acid SCHEMBL29433140 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotenic Acid SCHEMBL29466098 | 1.00 | CYP3A4 (1.00) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL9337024 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL14330777 | 0.92 | CYP3A4 (0.84) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL5482303 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL23139544 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL19560666 | 0.89 | RARA (0.82) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL29466100 | 0.89 | CYP3A4 (0.80) | CYP3A4CYP26A1RARBRARGRARA | |
| SCHEMBL17885756 | 0.88 | RARB (0.81) | CYP3A4CYP26A1RARBRARGRARA | |
| Tazarotene SCHEMBL995330 | 0.87 | RARB (0.88) | CYP3A4CYP26A1RARBRARGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1700855-B1 | A process for the preparation of tazarotene | FIDIA FARMACEUTICI (IT) | 2015-05-06 | — | — | EP | claimed |
| WO-2010067327-A1 | COSMETIC COMPOSITION CONTAINING ACETYLATED OLIGOGLUCURONANS | SEDERMA (FR) | 2010-06-17 | — | — | WO | claimed |
| WO-2009116075-A2 | PROCESS FOR PREPARATION OF TAZAROTENE | INDOCO REMEDIES LIMITED (IN) | 2009-09-24 | — | — | WO | claimed |
| EP-1003569-B1 | STERILE BIOERODIBLE IMPLANT DEVICE CONTAINING RETINOID WITH IMPROVED BIOCOMPATABILITY AND METHOD OF MANUFACTURE | ALLERGAN INC (US) | 2004-10-20 | — | — | EP | claimed |
| EP-0785782-B1 | USE OF DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN INC (US) | 2004-09-08 | — | — | EP | claimed |
| JP-2001513369-A | — | — | 2001-09-04 | — | — | JP | claimed |
| US-6258811-B1 | ADMINISTERING RETINOIC ACID RECEPTOR AGONIST | EISAI CO., LTD. (JP) | 2001-07-10 | — | — | US | claimed |
| EP-1025857-A1 | RETINOIC ACID AGONISTS AS PREVENTIVE AND THERAPEUTIC AGENTS FOR NEPHRITIS | Eisai Co., Ltd. (JP) | 2000-08-09 | — | — | EP | claimed |
| EP-1003569-A2 | STERILE BIOERODIBLE IMPLANT DEVICE WITH IMPROVED BIOCOMPATABILITY AND METHOD | Allergan Sales, Inc. (US) | 2000-05-31 | — | — | EP | claimed |
| EP-0930075-A1 | METHODS FOR PREVENTING, INHIBITING OR TREATING GRAFT REJECTION REACTIONS IN GRAFT-VERSUS-HOST DISEASE (GVHD) AND ORGAN TRANSPLANTATION | Eisai Co., Ltd. (JP) | 1999-07-21 | — | — | EP | claimed |
| WO-1999007418-A2 | STERILE BIOERODIBLE IMPLANT DEVICE WITH IMPROVED BIOCOMPATABILITY AND METHOD | ALLERGAN SALES, INC. (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0785782-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | Allergan (US) | 1997-07-30 | — | — | EP | claimed |
| WO-1996011686-A1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY | ALLERGAN (US) | 1996-04-25 | — | — | WO | claimed |
| EP-0284288-B1 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID LIKE ACTIVITY | ALLERGAN, INC (US) | 1992-05-27 | — | — | EP | claimed |
| US-5089509-A | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC. (US) | 1992-02-18 | — | — | US | claimed |
| EP-0284288-A1 | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | claimed |
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | KYOTO UNIVERSITY (JP) | 2026-02-26 | — | — | US | disclosed |
| US-12514834-B2 | Pharmaceutical composition for treating and/or preventing renal cystic ciliopathy | KYOTO UNIVERSITY (JP) | 2026-01-06 | — | — | US | disclosed |
| EP-0284288-A1 | Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity | ALLERGAN, INC (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0252003-A2 | Substituted aminoxy succinates and their application as stabilisers | CIBA-GEIGY AG (CH) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING RENAL CYSTIC CILIOPATHY | PKD1, RARB, PKD2 | CYP3A4 4441/4885CYP26A1 622/4885RARB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.